HLA-A and neoplasm: The use of these newly cloned tumor-reactive B*07:02, B*40:01, and C*03:04-restricted NY-ESO-1 TCR genes may widen the applicability of anti-NY-ESO-1 TCR gene therapy and immune mobilizing monoclonal TCRs against cancer (ImmTAC) therapy beyond HLA-A*02:01-positive cancer patients.